The most commonly reported side effects of fitusiran include chest pain, haemorrhage, and off label use, based on 12 FDA adverse event reports from 2025 to 2025.
Percentages show how often each reaction appears relative to total reports for fitusiran.
These are voluntary reports and do not establish that fitusiran caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
16.7% of fitusiran adverse event reports involve female patients and 83.3% involve male patients. The largest age group is adult at 78%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking fitusiran when the adverse event was reported.
Fitusiran is sold under the brand name Qfitlia.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.